Previous 10 | Next 10 |
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the "Company") today announced the pricing of its previously announced underwritten public offering of 1,898,735 shares of its common stock at a public offering price of $39.50 per share. The gross proceeds of the offering to the Co...
2023-05-11 17:45:25 ET ANI Pharmaceuticals ( NASDAQ: ANIP ) on Thursday announced a proposed stock offering. Shares of ANIP slipped 6% to $41.30 after hours. The company will offer all the shares to be sold in the offering. ANI said it would use the net proceed...
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI”) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by ANI. The offering is subject to market conditions, and th...
2023-05-08 13:35:19 ET ANI Pharmaceuticals, Inc. (ANIP) Q1 2023 Earnings Conference Call May 8, 2023, 8:30 AM ET Company Participants Judy DiClemente - Insight Communications Investor Relations Nikhil Lalwani - President and CEO Stephen Carey - Chief Financial Of...
2023-05-08 11:28:58 ET ANI Pharmaceuticals ( NASDAQ: ANIP ) stock rose ~11% on Monday after Q1 results beat estimates and the company raised its FY23 outlook. Adjusted EPS climbed to $1.17, compared to adjusted loss per share of -$0.12 in Q1 2022. Net revenues grew +65.6...
2023-05-08 10:03:22 ET Gainers: Immuron ( IMRN ) +49% . ANI Pharmaceuticals ( ANIP ) +17% . MiNK Therapeutics ( INKT ) +13% . Evaxion Biotech ( EVAX ) +8% . Predictive Oncology ( POAI ) +8% . Losers: Catalent ( CTLT ) ...
2023-05-08 06:56:54 ET ANI Pharmaceuticals press release ( NASDAQ: ANIP ): Q1 Non-GAAP EPS of $1.17 beats by $0.82 . Revenue of $106.79M (+65.6% Y/Y) beats by $23.31M . Raises Company net revenue guidance to $385 million to $410 million from $360 million to $38...
First Quarter 2023 Financial Results -- Record quarterly net revenues of $106.8 million, representing year-over-year growth of 65.6%; 2023 first-quarter net income available to common shareholders of $1.0 million and diluted GAAP income per share of $0.06 -- -- Record quarte...
2023-05-05 12:17:17 ET ANI Pharmaceuticals ( NASDAQ: ANIP ) is scheduled to announce Q1 earnings results on Monday, May 8th, before market open. The consensus EPS Estimate is $0.35 (+391.7% Y/Y) and the consensus Revenue Estimate is $83.48M (+29.5% Y/Y). Over the last ...
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2023 financial results on Monday, May 8, 2023, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Ste...
News, Short Squeeze, Breakout and More Instantly...
ANI Pharmaceuticals Inc. Company Name:
ANIP Stock Symbol:
NASDAQ Market:
ANI Pharmaceuticals Inc. Website:
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Po...
2024-07-09 17:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP....